Abstract
In our previous study, a protein engineering approach, accounting for the effects of single point mutations of the binding site residues on the stability of 22 thiazolo[4,5-d]pyrimidines in complex with the intracellular kinase domain of EGFR (PDB ID: 1XKK), was established in a systematic manner to be an efficient strategy for the identification of anti-EGFR-related-cancer drug candidates. The inhibitory activities of two lignad molecules, 4-(7-(3-chloro-4-morpholinophenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide and 4-(7-(4-morpholinophenylamino) thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide, exhibited some sort of uniqueness. Regardless of a slight mutual structural difference between these two ligands in only a peripheral Cl atom, their inhibitory activities against EGFR appeared to be associated with two quite opposite structural bases respectively. Herein, the fundamental rationalization of the remarkable standpoint is elaborated using both molecular docking and molecular dynamics simulations. Consequently, a number of implications of vital importance for the successful structure-based design of prospective drugs against EGFR-related cancers are discussed.
Keywords: Cancer, drug design, EGFR, inhibitor, ligand, single point mutation, thiazolo pyrimidine, tyrosine kinase.
Medicinal Chemistry
Title:Structural Elucidation of Unique Inhibitory Activities of Two Thiazolo[ 4,5-d]pyrimidines Against Epidermal Growth Factor Receptor (EGFR): Implications for Successful Drug Design
Volume: 10 Issue: 1
Author(s): Petar M. Mitrasinovic
Affiliation:
Keywords: Cancer, drug design, EGFR, inhibitor, ligand, single point mutation, thiazolo pyrimidine, tyrosine kinase.
Abstract: In our previous study, a protein engineering approach, accounting for the effects of single point mutations of the binding site residues on the stability of 22 thiazolo[4,5-d]pyrimidines in complex with the intracellular kinase domain of EGFR (PDB ID: 1XKK), was established in a systematic manner to be an efficient strategy for the identification of anti-EGFR-related-cancer drug candidates. The inhibitory activities of two lignad molecules, 4-(7-(3-chloro-4-morpholinophenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide and 4-(7-(4-morpholinophenylamino) thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide, exhibited some sort of uniqueness. Regardless of a slight mutual structural difference between these two ligands in only a peripheral Cl atom, their inhibitory activities against EGFR appeared to be associated with two quite opposite structural bases respectively. Herein, the fundamental rationalization of the remarkable standpoint is elaborated using both molecular docking and molecular dynamics simulations. Consequently, a number of implications of vital importance for the successful structure-based design of prospective drugs against EGFR-related cancers are discussed.
Export Options
About this article
Cite this article as:
Mitrasinovic M. Petar, Structural Elucidation of Unique Inhibitory Activities of Two Thiazolo[ 4,5-d]pyrimidines Against Epidermal Growth Factor Receptor (EGFR): Implications for Successful Drug Design, Medicinal Chemistry 2014; 10 (1) . https://dx.doi.org/10.2174/157340641001131226122124
DOI https://dx.doi.org/10.2174/157340641001131226122124 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Epidermal Cell Proliferation in Calorie-Restricted Aging Rats
Current Aging Science MicroRNAs in Renal Cell Carcinoma
MicroRNA Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Technological Advances in Antigen Delivery and Synthetic Peptide Vaccine Developmental Strategies
Mini-Reviews in Medicinal Chemistry Chitosan - A Potential Polymer to Prepare Anticancer Drug Delivery Systems: Patent Review
Recent Patents on Anti-Cancer Drug Discovery Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Natural Polymer-based Stimuli-responsive Hydrogels
Current Medicinal Chemistry Clinically Relevant Reprogramming to Pluripotency
Recent Patents on Regenerative Medicine Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Reviews on Recent Clinical Trials Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry Xolair in Asthma Therapy: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Managing Expectations in the Transition to Proof of Concept Studies
Reviews on Recent Clinical Trials 4'-Thionucleosides as Potent and Selective A<sub>3</sub> Adenosine Receptor Ligands
Current Organic Chemistry Genomics and Public Health Research: Building Public “Goods”? Divergences and Convergences of Views in Four Stakeholder Groups
Current Pharmacogenomics and Personalized Medicine The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease
Current Pharmaceutical Design The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Current Chemical Biology Haploinsufficiency of DNA Damage Response Genes and their Potential Influence in Human Genomic Disorders
Current Genomics